You state..
"We fully believe in the outstanding potential of Bavituximab, and we are very, very concerned that our second major stockholder does not. MSK believes in us, but for some reason, Ronin disagrees with MSK."
I don't think ronin has stated that... ronin says monetize the ip and put it in capable hands... even if pphm were to continue to develop the ip, i doubt the market would recognize any value creation due to the turd factor outlined in a previous post... if msk has a high opinion of the tech, ronin will get the value.. and a stronger institution will get more shots on goal and better access to patients...
pphm cannot sell shares at 20% of paid in capital to fund trials and the ip cannot sit on the sidelines while the i-o world is going at warp speed...
from the ronin letter
Peregrine must immediately cease all clinical development activities, adjust its cost structure accordingly, and begin a process to monetize its intellectual property, either through an outright sale or a contingent value right to a larger pharmaceutical firm that has the financial ability to underwrite further studies. Peregrine's losses are entirely attributed to its roughly $30 million in annual clinical development activities. By stopping clinical development activities and monetizing the intellectual property, many of Peregrine's problems will automatically be solved, as it will no longer be deeply unprofitable or need to constantly dilute stockholders at such a rapid rate. Furthermore, this will enable Peregrine to focus on profitably growing Avid, which will no longer have to internally compete for capital with the extremely risky clinical development spending.
News 
Market Data 
Discover 
AI
